Irrelevance of Explicit Cost–effectiveness Thresholds When Coverage Decisions Can Be Reversed
Expert Review of Pharmacoeconomics and Outcomes Research - United Kingdom
doi 10.1586/erp.13.8
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2013
Authors
Publisher
Informa UK Limited